Merck Group and Illumina were among the investors in a $13.2m round, along with Idinvest Partners, Kurma Partners and existing backer Sofinnova Partners.
France-based life sciences startup DNA Script secured €11m ($13.2m) yesterday in a series A round featuring corporate venturing subsidiaries of pharmaceutical firm Merck Group and genetics technology producer Illumina.
Merck Ventures BV and Illumina Ventures were joined by venture capital firm Sofinnova Partners, private equity firm Idinvest Partners and healthcare-focused investment firm Kurma Partners. Sofinnova is an existing backer, though DNA Script has not revealed details of earlier funding.
DNA Script is developing enzymatic technology that aims to expedite the…
